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OBJECTIVE: To evaluate the analytical micromethod using liquid chromatography for the quantification of propranolol in
children submitted to surgery of tetralogy of Fallot (TLF). Methods: Only 0.2 mL of plasma is required for the assay. Peaks eluted
at 8.4 (Propranolol) and 17.5 min (verapamil, internal standard) from a C18 column, with a mobile phase 0.1 M acetate buffer, pH
5.0, and acetonitrile (60:40, v/v) at flow rate 0.7 mL/min, detected at 290 nm (excitation) and 358 nm (emission). Surgery was
started 776 min of drug administration (8.7mg, mean); seven blood samples were collected from six patients (4M/2F; 2.1yrs;11.5kg;
0.80m; 18.9kg/m2).
RESULTS: Confidence limits of the method showed high selectivity and recovery, sensitivity of 0.02ng/mL, good linearity (0.05-
1000ng/mL), precision of 8.6% and accuracy of 3.1%. The mean duration of surgery was 283.2min, with the patients remaining
under cardiopulmonary bypass (CPB) for 114min. A declining curve of propranolol plasma concentration was obtained after the
last dose in the night that preceded the day of surgery. Plasma concentration also was normalized with hematocrit due to the
hemodilution caused by the CPB procedure. On the other hand a decrease on drug plasma concentration was obtained between
periods, the beginning of surgery to the postoperative day 2 (7.09 ng/mL and 0.05 ng/mL, p<0.05 respectively) and from the end
of CPB to the postoperative day 2 (2.79ng/mL e 0.05ng/mL, p<0.05).
CONCLUSION: Propranolol monitoring of plasma concentrations of children (TLF) normalized after the last preoperative dose
revealed a decline from the beginning of surgery to the second postoperative day, suggesting that, once redistribution was restored,
propranolol washout was complete.
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INTRODUCTION
Tetralogy of Fallot accounts for 10% of all congeni-
tal heart diseases and is the most common cyanotic heart
disease during infancy1. Few children are asymptomatic
and, by the age of 4 months, most of them develop cya-
nosis which is normally progressive, a fact leading to de-
layed growth and development. In addition, fatigue and
breathlessness during exercise and episodes of hypoxia are
common in these patients. Beta-adrenergic receptor
blockers are of great therapeutic value in the care of pa-
tients with functional obstruction of ventricular flow. In
this respect, propranolol is used successfully in three situ-
ations: management of an acute dyspnea attack, preven-
tion of episodes of dyspnea, and improvement of the clini-
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cal conditions of children who await for surgical correc-
tion. On the other hand, there is a disadvantage in clini-
cal practice because propanolol may cause serious respi-
ratory problems, changes in cardiac output and cardiac
insufficiency, all  related to the high doses of propranolol
required to maintain efficacy 2. Patients with tetralogy of
Fallot should be submitted to surgical correction consist-
ing of the closure of the ventricular septal defect with al-
leviation of right ventricular flow obstruction 3, 4, 5. Ad-
ministration of propranolol during the preoperative period
is advantageous and reduces the incidence of ischemic
events, hypertension and secondary tachyarrhythmias 6.
Because cardiopulmonary bypass (CPB) and hypothermia
cause changes in plasma propranolol concentrations, drug
monitoring during and after surgery becomes important.
Different methods have been developed to determine
plasma propranolol concentrations, including fluorimetry
7, 8, 9
, gas chromatography 10, and high-performance liquid
chromatography with fluorescence detection (HPLC-F) 11-
16
. More recently, an analytical method for the quantifica-
tion of propranolol in plasma of postoperative adult patients
was proposed by Pereira et al (2000). Although this method
was found to be selective, its sensitivity was relatively low
for our purpose. Therefore, once the washout of propranolol
was investigated in pediatric patients undergoing surgical
correction of tetralogy of Fallot, the objective of the present
study was to optimize a new method with high sensitivity
to determine lower propranolol plasma concentrations in
the perioperative period.
EXPERIMENTAL
Clinical protocol and blood sample collection
The study protocol was approved by the Ethics Com-
mittees of the Institutions participating of the investigation.
Before inclusion in the study, the parents or legal repre-
sentatives of all children provided a written informed con-
sent to participate of the study. Patients using vasoactive
drugs, with episodes of bronchospasm, or without indica-
tion for a beta-blocker drug were excluded from the study.
 Table 1 summarizes the individual characteristics of six
patients with tetralogy of Fallot with surgical indication for
the corrective repair of the congenital anomaly. Patients al-
located for the study were children of both sexes (4M/2F)
11.5+/-3.9 kg, 2.1+/-1.3 yrs, 0.8+/-0.1 m (height), 18.9+/-
6.4 kg/m2 (body mass index). They received a long term
treatment dose adjusted (1 to 3 mg/kg of propranolol, three
Table 2. Last dose administered before surgery and interval between the administration of the last preoperative propranolol
dose and the beginning of surgery.
Allocation Last preoperative Time between Duration Duration Ht% Ht%
 dose (mg)  last dose and  of surgery of CPB Begin of  CPB
begin of surgery  (min) (min) (min)  surgery
1 10 600 360 120 43 23
2 10 720 240 110 38 21
3 10 636 230 100 40 22
4 10 720 241 100 46 27
5 5 1362 190 116 34 15
6 5 618 438 138 50 19
Mean 8.3 776.0 283.2 114.0 41.8 21.2
SD 2.6 291.6 94.9 14.3 5.7 4.0
95%CI 6.3-10.4 542.7-1009.3 207.2-359.1 102.6-125.4 37.2-46.4 17.9-24.4
CPB: cardiopulmonary bypass; Ht: hematocrit; SD: standard deviation; 95% CI: upper and lower limits of the 95% confidence interval.
Table 1. Characteristics of the patients studied and daily dose of propranolol administered in the preoperative period.
Patient Gender Age (years) Weight (kg) Height (m) BMI (kg/m2) Daily dose mg/kg/day
1 M 0.6 9.9 0.8 17.6 9.0
2 M 2.7 13.2 0.9 16.3 1.5
3 F 2.2 12.9 0.9 16.7 4.5
4 M 4.0 16.5 0.7 31.8 1.8
5 M 2.6 11.3 0.9 15.2 5.4
6 F 0.5 5.0 0.6 15.9 3.0
Mean - 2.1 11.5 0.8 18.9 4.2
SD - 1.3 3.9 0.1 6.4 2.8
95%CI - 1.0- 3.2 8.4- 14.6 0.7- 0.9 13.8 – 24.0 2.0 – 6.4
BMI: body mass index; SD: standard deviation; 95% CI: upper and lower limits of the 95% confidence interval.
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times a day) in the ambulatory as follows: 4.2+/-2.8 mg/
kg a day, orally.
The last preoperative dose was administered the night
before the day of surgery. The interval between the last dose
and the beginning of surgery, the duration of surgery and
of the CPB, and the hematocrit value are summarized in
Table 2 as individual and population data.
Seven blood samples (2 mL each) were collected at the
following times: at the beginning of surgery, at the begin-
ning of CPB, during CPB, at the end of CPB, at the end of
surgery, and 24 and 48 h after surgery. Blood was collected
into tubes containing EDTA sodium, centrifuged at 3000
g for 30 min, and plasma was stored at -20ºC until assay;
total volume of blood collected was lower than 20 mL. The
samples were analyzed in parallel to the calibration daily
curve and internal controls in three different concentrations
(low, medium and high). Data obtained from patients were
normalized with hematocrit before surgery using the fol-
lowing equation:
C
n
 = (C
ob) x (Ht% basal / Ht% period)
where,
Normalized and obtained data were plasma concentra-
tions of the drug
Ht basal: hematocrit before surgery
Ht period: hematocrit obtained in each period
Analytical procedure
Liquid–liquid extraction for the clean-up of biological
sample
A simple liquid-liquid extraction was employed for the
determination of propranolol plasma levels. For this, 0.2 mL
aliquots of plasma were added to 0.2 mL internal standard
(10 mg/L verapamil hydrochloride, 250ng/assay), 0.2 mL
1.25 M sodium hydroxide and 3 mL dichloromethane. Then,
the mixture was vortexed for 1 min and centrifuged at 3000
g for 30 min. The supernatant was aspirated and discarded;
the tube containing the organic phase was immersed in a liq-
uid nitrogen bath, and the organic extract was carefully trans-
ferred to a conic tube and concentrated to dryness under a
nitrogen flow in a water bath at 37oC. Next, the dry extract
was dissolved with 0.2 mL of a mixture of acetonitrile and
water (8:2,v/v) and 0.02 mL volumes were injected auto-
matically into the liquid chromatograph.
Chromatographic analysis
The samples were analyzed by HPLC-F in a
Shimadzu LC-10A liquid chromatograph (Kyoto, Japan)
using a Shim-Pack CLC ODS C18 reverse-phase column
(Shimadzu; 5 micron, 150 x 6.0 mm length x internal
diameter) adapted to an insert NovaPak C18 Waters
Assoc. (Milford, USA). The binary mobile phase con-
sisted of 0.1 M acetate buffer, pH 5.0, and acetonitrile
(60:40, v/v) at a flow rate of 0.7 mL/min in an isocratic
elution system. The peaks were monitored with an RF
10 AXL fluorescence detector (Shimadzu) at excitation
and emission wavelengths of 290 and 358 nm, respec-
tively. The peak areas for propranolol and the internal
standard were integrated using a Chromatopac CR-6A
integrator Shimadzu (Kyoto, Japan).
Validation of the analytical method
The calibration curve was obtained using aliquots of
a stock solution of the drug (1 mg/mL) diluted in drug-
free human plasma (blank) and stored at -20ºC. The fol-
lowing concentrations of the standard propranolol solu-
tion in plasma were prepared: 1000, 500, 100, 50, 25,
10, 5, 2.5, 1, 0.5, and 0.05 ng/mL. The internal stand-
ard, verapamil hydrochloride (10 mg/L, working solu-
tion) was prepared from a stock solution (1000 mg/L,
aqueous) distributed in small aliquots and stored at -20ºC
until assay.
Each nominal propranolol plasma concentration was
plotted against the respective peak area ratio obtained
for the drug and its internal standard; in addition the lin-
ear correlation coefficient (r2> 0.98) and its respective
equation (Y = AX + B) were calculated. At least five of
the nine calibration standards were considered for the
construction of the daily calibration curve (0.05-100 ng/
mL).
The internal controls (80, 40 and 0.5 ng/mL) were pre-
pared in duplicate and analyzed during each analytical run
to guarantee the acceptance of daily calibration curve. An
analytical run was accepted when at least four of the six
controls presented a deviation of less than 15% (for high
and medium controls) or less than 20% (for the low con-
trol) from the nominal concentration. Then, the calibra-
tion curve was applied to quantify propranolol in plasma
samples collected from patients included in the clinical
protocol.
The linearity of the method was determined using ten
propranolol concentrations in triplicate. The detection and
quantification limits were evaluated based on the analysis
of 10 replicates. The quantification limit was defined as
the lowest plasma concentration of the daily calibration
curve quantified with acceptable precision and accuracy.
The detection limit was defined as one half of the quanti-
fication limit. Absolute recovery was determined using
three drug concentrations (80, 40 and 0.5 ng/mL) in five
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replicates and expressed as percentage. The accuracy of the
method was evaluated using three concentrations (low, me-
dium and high) in six replicates, and the systematic error
of the assay was determined based on the percentage of
inaccuracy. Intra-day precision was determined based on
the analysis of three concentrations in duplicate, whereas
inter-day precision was evaluated by the duplicate analy-
sis of three concentrations (80, 40 and 0.5 ng/mL) on three
consecutive days, for a total of 18 assays.
For the determination of the stability of propranolol in
plasma, less than 15% (highest concentration) and 20%
(lowest concentration) variation was adopted as an accept-
able criterion for all concentrations studied. Stability was
analyzed after three freezing/thawing cycles of the drug in
the biological sample. For the analysis, samples of two pro-
pranolol concentrations (250 and 16 ng/mL) were analyzed
in triplicate on 3 consecutive days, corresponding to freez-
ing/thawing cycles 1, 2 and 3.
The short-, medium- and long-term stability of the
drug was also analyzed. Stability was evaluated as a func-
tion of time and storage conditions using extracted sam-
ples, in at least three concentrations (16, 62.5 and 250ng/
mL) in replicates (n=3) kept at room temperature on the
tray of the auto-sampler for the maximum time any sam-
ple could remain in this condition. For the determination
of short-term stability, two concentrations were submit-
ted to three freezing/thawing cycles in triplicate for each
cycle. Long-term stability was determined using two con-
centrations (8 and 500 ng/mL) in replicates (n=3) stored
for different periods of time up to 12 months, thus guar-
anteeing stability during the study period; the results are
reported as percentage.
Robustness of the method was determined using two
analytical C18 columns of different batches supplied by the
same manufacturer, and using small variations in the pro-
portion of the constituents and in the flow rate of the mo-
bile phase. Six replicates were analyzed and the results are
reported as a function of the coefficient of variation. The
influence of room temperature variations could be ruled out
since the temperature in the laboratory was monitored twice
daily and was kept at 21 ± 2ºC.
Statistical analysis and calculation of the mean
residence time
The normalized plasma propranolol concentrations were
plotted as a function of sampling time. The mean residence
time of the drug was determined using the PK Solutions
2.0, Non Compartment Data Analysis software (Ashland
OH, USA).
The GraphPad Instat software 3.0 (GraphPad Instat Inc.,
San Diego CA, USA) was used for statistical analysis, and
paired data were compared by ANOVA and Wilcoxon or
Friedman tests. The results are reported as median, 95%
confidence interval (95% CI) for drug concentration. The
characteristics of patients were expressed as mean +/-stand-
ard deviation of the mean.
RESULTS
Validation of the analytical method
The specificity of the analytical method for the quanti-
fication of propranolol in biological samples was evaluated
by injecting extracts of normal (n=2), lipemic (n=2) and
hemolysate (n=2) plasma into the chromatographic system.
The endogenous components eluted from the chromato-
graphic column did not interfere with the analysis under
the conditions described above, with the chromatogram
peaks obtained for the endogenous components differing
from the retention times obtained for propranolol and the
internal standard (verapamil), as can be seen in Figure 1.
The peaks corresponding to propranolol and internal
standard were eluted from the chromatographic column at
8.4 and 17.5 min, respectively. The chromatographic pro-
file of the determination of propranolol in plasma is shown
in Figure 2, which illustrates the analysis of a plasma blank,
blank of plasma sample spiked (propranolol 5ng/mL,
plasma standard) with addition of the internal standard and
plasma of a patient receiving propranolol. Detection by
fluorescence (290 nm and 358 nm for excitation and emis-
sion wavelengths, respectively) showed high sensitivity and
good selectivity. The total time required for each chroma-
tographic run was 20 min.
The daily calibration curve (Figure 3) showed excellent
linearity (r2 : 0.9998), and only 0.2 mL of the biological
sample was required. Thus, the new analytical HPLC-F
method proposed was selective and sensitive for the quan-
 Figure 1: Chromatographic profiles of plasma propranolol and its internal
standard (verapamil). Chromatograms: (A)Normal plasma (B) Lipemic
plasma (C) Hemolysate plasma.
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tification of propranolol in plasma using a C18 column, a
binary mobile phase and low flow rate.
The method developed presented high sensitivity (quan-
tification limit = 0.05 ng/mL and detection limit = 0.02
ng/mL), linearity in the range of 0.05 to 1000 ng/mL with
a linear coefficient of 0.9998, good recovery (97%), and
acceptable precision (intra-day 4.7% and inter-day = 8.6%)
and accuracy (3.1%). In addition data from studies of sta-
bility and robustness were included (Table 3 - 4).
Robustness of the method was analyzed based on analy-
sis using different C18 columns (1.5%), variations in the
composition or final pH of the mobile phase (6.4%), or in
the flow rate (2,4%), as a function of the coefficient of vari-
ation.
Analysis of the stability on freezing/thawing cycle
showed that propranolol concentration remained stable for
at least three cycles for the two concentrations analyzed
in triplicate (16 and 250 ng/mL), with a good coefficient
of variation, as seen in Table 4.
The maximum time the sample remains on the tray of
the automatic injector before analysis showed that pro-
pranolol remained stable for a least 18 h. The procedure
was conducted for different concentrations (16, 62.5 and
250 ng/mL, replicates n=3) and a coefficient of variation
equivalent to 3.8% was obtained, as shown in Table 4.
Regarding long-term stability, propranolol standards in the
biological sample were found to be stable in a freezer (-20°C)
for a minimum period of 24 months; a coefficient of varia-
tion of 0.8% was obtained for the assay performed in tripli-
cate for propranolol high and low concentrations (500 and 8
ng/mL, respectively) in blank plasma spiked (Table 4).
Therapeutic drug monitoring
The validated analytical method was applied for drug
monitoring of plasma concentrations in six patients under-
going heart surgery for the correction of a congenital
anomaly (tetralogy of Fallot). Analyses were performed
using a daily calibration standard curve accepted by the in-
ternal controls and propranolol plasma concentrations in
patient samples were estimated by the linear regression
equation.
Table 4. Stability studies of propranolol in biological
matrices
Concentration Variation
Stability after three freeze-thaw cycles 16ng/mL 8.6%
250ng/mL 7.3%
Short-term stability 16ng/mL 1.5%
62.5ng/mL 2.4%
250ng/mmL 7.5%
Long-term stability 8ng/mL 1.3%
500ng/mL 0.5%
Table 3. Confidence limits of the analytical method for the
determination of propranolol in plasma.
Parameters Unit Propranolol
Linearity ng/mL 0.05-100
Linear correlation coefficient (r2) r2 : 0.9998
Detection limit ng/mL 0.02
Quantification limit ng/mL 0.05
Absolute recovery (80, 40 e 0.5ng/mL) (%) 95.0
Precision (80, 40 e 0.5ng/mL)
·Inter-day (mean, SD) (%) 8.6+/-3.9
·Intra-day (%) 4.7+/- 4.3
Systematic error  (inaccuracy)
(80, 40 e 0.5ng/mL) (%) 3.1+/-2.9
Robustness (mean)
·C18 columns (2 batches). (CV%) 1.5
·Flow rate (+/- 0.1mL) (CV%) 2.4
·Mobile phase
(+/- 1%  in the proportion of acetonitrile) (CV%) 6.4
SD: standard deviation; CV: coefficient of variation.
Figure 2: Chromatographic profile of plasma propranolol and its internal
standard (verapamil). Chromatograms: (A) Blank of plasma samples without
internal standard (IS), (B) blank of plasma sample spiked (propranolol 5ng/
mL) plus IS. (C) plasma of a patient receiving propranolol. Retention times:
1) Propranolol 8.4 min and, 2) Verapamil (IS) 17.5 min.
Figure 3. Calibration daily curve of propranolol in plasma, blank plasma
spiked to obtain six concentrations of propranolol.
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The mean duration of surgery was 5.03 h (301.7 ± 99.6
min), with the patient remaining under CPB for 1.94 h
(116.3 ± 14.4 min). Surgery was started 12.74 h (794.9 ±
270.8 min) after administration of the last dose of pro-
pranolol (8.7 ± 2.7 mg), as shown inTable 2.
The declining curve of propranolol plasma concentra-
tion obtained from patients after the last dose in the night
that preceded the day of surgery is illustrated in Figure 4.
The effect of hemodilution that occurs during the sur-
gical intervention on propranolol plasma concentrations
(data obtained and data normalized with hematocrit) was
investigated by comparison. It showed no significant dif-
ference at the beginning of surgery (7.09 and 7.09 ng/mL,
p=1.0000) as well as at the end of surgery (2.70 and 2.94
ng/mL, p=0.1250), Table 5. However, significant differ-
ences were observed by comparison of drug concentrations
(obtained versus normalized) during CPB (1.14 versus 2.06
ng/mL, p=0.0313) and after the CPB (2.79 versus 3.37 ng/
mL, p=0.0313), as seen in Table 5.
On the other hand, by comparison between periods, nor-
malized data showed a significant decrease on drug con-
centrations (p<0,05) from the beginning of surgery (7.09
ng/mL) to the postoperative day 2 (0.05 ng/mL) and also,
a significant reduction from the end of CPB (2.79ng/mL)
to the postoperative day 2 (0.05ng/mL, p<0.05).
Finally, by applying a noncompartmental analysis PK
solutions 2.0 software, the mean residence time estimated
for propranolol during the period of study was 35.8 h.
DISCUSSION
Validation of the analytical method
Before the quantification of drug by HPLC-F, with respect
to the clean-up of the biological sample, Heeden (1991) de-
scribed a selective but expensive procedure consisting of solid
extraction of propranolol from plasma using Bond Elut col-
umns using two extraction steps. The minimum detectable
concentration was 1.0 ng in 1mL plasma. In the present study,
simple liquid-liquid extraction with dichloromethane, proposed
to quantify propranolol plasma concentrations, presents an
absolute recovery comparable to those reported previously
with a relative low cost method 11, 13, 18. A detection limit of
20 ng/mL using 0.4 mL plasma was described by Lo and
Riegelman (1980), whereas Drummer et al (1981), Harrison
et al (1985) and Pereira et al (2000) reported for assays em-
ploying higher volumes of plasma, detection limits of 2, 1 and
0.5 ng/mL, respectively. In the present method, 0.02 ng/mL
was determined by our procedure, once the detection limit was
increased by 20 times compared to Pereira et al, 2000.
As regards chromatographic systems previously de-
scribed, ion-pair liquid chromatography requires modify-
ing reagents added to the mobile phase, such as alkylamines
(triethylamine) and sulfonic acids, in addition to a high flow
rate for elution of the analyte. On the other hand, reverse-
phase liquid chromatography using an isocratic elution sys-
tem has been preferred over those previously described.
Consequently, in the present study the binary system us-
ing reverse-phase chromatography was found to be the best
alternative among the most complex systems reported in
the literature 14-16, 19. Despite the good selectivity obtained
with complex systems, an evident limitation of the reported
methods is the high flow rate (1.5-2.0 mL/min) required
to elute the drug 11-13, 20, 21.
Table 5. Comparison of propranolol plasma concentrations during the surgery in patients with tetralogy of Fallot, medians,
n=6.
Period data obtained ng/mL(IC95%) normalised data ng/mL(IC95%) Probability  (p)Wilcoxon  test a
Beginning of surgery 7.09(1.76-15.80) 7.09(1.76-15.80) p=1.0000
End of surgery 2.70(1.22-4.68) 2.94(1.27-5.66) p=0.1250
Beginning of CPB 2.69(0.44-8.56) 2.87(0.58-8.60) p=0.5000
Intra - CPB 1.14(0.24-4.29) 2.06(0.49-8.91) p=0.0313
End of CPB 2.79(1.45-8.52) 3.37(1.31-11.57) p=0.0313
PO 1st day 0.63(0.00-3.88) 2.28(0.51-4.21) p=0.4375
PO 2nd day 0.05(0.00-2.31) 0.05(0.00-1.92) p=0.9999
CPB: cardiopulmonary bypass; PO: postoperative period. a Nonparametric statistical analysis for paired data; p<0.05, significance level; data obtained
versus data normalised with hematocrit.
Figure 4 - Propranolol plasma levels (medians, n:6), during the surgery
with hypothermic cardiopulmonary bypass, after the last administered dose
in the preoperative of 8,86mg, normalized relative to the hematocrit.
221
CLINICS 2007;62(3):215-24 Propranolol plasma monitoring in children submitted to surgery
Sanches C et al.
Some modifications introduced in the present method
provided a marked increase in the sensitivity, thus re-
quiring validation of the new procedure compared to the
procedure described by Pereira and co-workers (2000)
once a highly sensitive procedure able to determine
picogram amounts of the drug in the plasma is neces-
sary to investigate the washout of propranolol. The main
adaptations responsible for the 20-fold increase in the
sensitivity of the method were the use of a mobile phase
consisting of a different proportion of acetate buffer, pH
5.0, and acetonitrile (60:40, v/v, instead of 65:35), a re-
duction in the ionic strength of the medium using 0.1
M instead of 0.4 M acetate buffer, pH 5.0, as proposed
by Pereira et al (2000) and, finally, replacement of the
analytical Nova Pak C18 column (150 x 3.9 mm, 4 µm;
Waters, Milford, USA) with a column of higher capac-
ity and selectivity (Shimpack ODS, 150 x 6 mm, 5 mi-
cron; Shimadzu), this modification leading to a marked
increase in sensitivity with an additional gain of selec-
tivity and capacity. The method validated was superior
to previously reported procedures , because 0.05 ng/mL
could be quantified by HPLC-F in 0.2 mL of plasma.
Thus, the binary reverse-phase chromatography system
described in the present study seems to be the best
choice in view of its selectivity, marked sensitivity, and
operation at low flow.
Analysis of the robustness of the method demonstrated
its reproducibility. In addition, propranolol was found to
be stable under the conditions analyzed, considering its
short-term stability (freezing/thawing cycle), stability over
time and under the storage condition used, and long-term
stability. It should be emphasized that no stability or ro-
bustness studies were performed earlier.
Quantification of propranolol in plasma of patients
submitted to surgical correction of tetralogy of Fallot
In outpatients with tetralogy of Fallot chronically
treated with propranolol, the effective plasma levels of the
drug should range from 40 to 90 ng/mL 22. A reduction
in the propranolol dose before heart surgery is necessary
to prevent complications during the intervention includ-
ing a low cardiac output in the postoperative period. On
the other hand, administration of propranolol before sur-
gery prevents episodes of hypoxemia during the induc-
tion of anesthesia. However, the recommended period for
discontinuation of the drug prior to the surgery is still con-
troversial. Barazzone and co-workers (1988) proposed an
interval of 6 to 8 h after the last propranolol dose, whereas
other investigators recommend a longer period ranging
from 12-18 h up to 24 h (maximum) before the begin-
ning of the surgical procedure 6, 17.
For interpretation of the results (Table 5), plasma pro-
pranolol concentrations were normalized to measure the
effect of hemodilution caused by the CPB during the sur-
gery. As can be seen, the obtained and normalized data de-
clined differently during CPB, p<0.05. Due to re-heating
of the patients at the end of CPB, obtained and normal-
ized plasma propranolol concentrations again increased dif-
ferently, p<0.05. According to Barazzone et al (1988), this
increase is mainly due to redistribution of the drug from
the lungs to the plasma, a reduction in hepatic metabolism,
and a decrease in the volume of distribution as a result of
hypothermia. In addition, a reduction in plasma proteins
increases the free fraction of the drug by 6.6 to 13.5%, be-
cause 90% of propranolol is bound to plasma protein, es-
pecially alpha 1-acid glycoprotein. On the other hand, when
CPB is installed and hemodilution occurs, the plasma pro-
pranolol concentration decreases by 50%. In addition, fat-
soluble drugs such as propranolol are easily sequestered by
the circulator, a fact that contributes to a reduction of
plasma propranolol levels during CPB 6.
In the present study, surgery was started about 15h af-
ter administration of the last preoperative propranolol
dose. Barazzone and co-workers (1988), investigating pa-
tients with tetralogy of Fallot who received propranolol,
PO, every 8 h before surgery, reported a median plasma
concentration of 18.7 ng/mL (95% CI, 3.4-61.5) at the be-
ginning of CPB, whereas in the present study a median
plasma concentration of 2.87 ng/mL (0.49-8.91) was ob-
served. This difference might be explained by the differ-
ent time intervals between the last preoperative dose ad-
ministered and the beginning of CPB, which was approxi-
mately 15 h in the present study versus 8 h in the inves-
tigation of Barazzone et al (1988). In addition, plasma
propranolol concentration was 2.28 ng/mL (0.51-4.21) 24
h after the beginning of surgery, i.e., during the late post-
operative period, compared to 1.0-5.6 ng/mL reported by
Barazzone et al (1988). In fact, concentrations found were
lower than the recommended to maintain efficacy (40-90
ng/mL); our data suggests that the washout of propranolol
was completed by the second postoperative day as dem-
onstrated by the mean residence time of drug.
CONCLUSION
The validated analytical method showed good linear-
ity, sensitivity, accuracy and precision for the determina-
tion of propranolol in plasma at low concentrations. Ro-
bustness and stability studies were acceptable.
The effect of hemodilution on propranolol plasma con-
centrations during CPB procedure was verified. Drug moni-
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toring after the last preoperative dose revealed a decline
of plasma concentrations, data normalized, from the begin-
ning of surgery up to the second postoperative day, sug-
gesting that, once redistribution was restored at the end of
surgery, propranolol washout was complete.
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RESUMO
Sanches C, Galas FRBG, Silva AGO de M, Carmona MJC,
Auler Jr. JO, Santos S R CJ. Monitoramento do propranolol
plasmático em crianças operadas da tetralogia de Fallot
através de micrométodo utilizando a cromatografia líquida
de alta eficiência. Clinics. 2007;62(3):215-24.
OBJETIVO: Avaliar o micrométodo analítico empregando
a cromatografia líquida para quantificação de propranolol
em crianças operadas de tetralogia de Fallot (TLF).
MÉTODO: Requereu-se apenas volumes de 0,2mL de
plasma para a realização do ensaio. Os picos foram eluídos
em 8.4 (Propranolol) e 17.5 min (verapamil, padrão interno)
de uma coluna C18, com fase móvel (tampão acetato 0,1
M pH 5,0 e acetonitrila, 60:40, v/v) em fluxo de 0,7 mL/
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min, sendo detectados em 290 nm (excitação) e em 358
nm (emissão). A cirurgia iniciou-se 776 min depois da dose
administrada (8,7mg, média) e sete amostras de sangue
foram coletadas de seis pacientes (4M/2F; 2,1 anos;11,5kg;
0,80m;18,9kg/m2).
RESULTADOS: Os limites de confiança do método
analítico evidenciaram alta seletividade e recuperação,
sensibilidade (0,02ng/mL), boa linearidade (0,05-1000ng/
mL), precisão de 8,6% e exatidão de 3,1%. A duração
média da cirurgia foi de 283,2min, com os pacientes em
circulação extracorpórea (CEC) durante 114min. Uma
curva de declínio do propranolol no plasma foi obtida
após a última dose na noite que precedeu o dia da
intervenção. A concentração plasmática foi normalizada
com o hematócrito devido à hemodiluição causada pela
CEC. Por outro lado obteve-se decréscimo nas
concentrações plasmáticas entre os períodos início da
cirurgia para o 2o dia de pós-operatório (7,09 ng/mL e0,05
ng/mL, p<0,05 respectivamente) e do final da CEC para
o 2o dia de pós-operatório (2,79ng/mL e 0,05ng/mL,
p<0,05).
CONCLUSÃO: O monitoramento das concentrações
plasmáticas normalizadas do propranolol, em crianças com
TLF, após a última dose pré-operatória revelou decaimento
do início da cirurgia para o segundo pós-operatório,
sugerindo que após a correção cirúrgica, uma vez restaurada
a distribuição, a eliminação do fármaco foi completa.
UNITERMOS: Propranolol, Micrométodo, Concentrações
plasmáticas, Tetralogia de Fallot.
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